American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults
- PMID: 37139824
- PMCID: PMC12478568
- DOI: 10.1111/jgs.18372
American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults
Abstract
The American Geriatrics Society (AGS) Beers Criteria® (AGS Beers Criteria®) for Potentially Inappropriate Medication (PIM) Use in Older Adults is widely used by clinicians, educators, researchers, healthcare administrators, and regulators. Since 2011, the AGS has been the steward of the criteria and has produced updates on a regular cycle. The AGS Beers Criteria® is an explicit list of PIMs that are typically best avoided by older adults in most circumstances or under specific situations, such as in certain diseases or conditions. For the 2023 update, an interprofessional expert panel reviewed the evidence published since the last update (2019) and based on a structured assessment process approved a number of important changes including the addition of new criteria, modification of existing criteria, and formatting changes to enhance usability. The criteria are intended to be applied to adults 65 years old and older in all ambulatory, acute, and institutionalized settings of care, except hospice and end-of-life care settings. Although the AGS Beers Criteria® may be used internationally, it is specifically designed for use in the United States and there may be additional considerations for certain drugs in specific countries. Whenever and wherever used, the AGS Beers Criteria® should be applied thoughtfully and in a manner that supports, rather than replaces, shared clinical decision-making.
Keywords: Beers criteria; Beers list; inappropriate prescribing; medications and drugs; older adults.
© 2023 The American Geriatrics Society.
Conflict of interest statement
CONFLICT OF INTEREST STATEMENT
Drs. Brandt, Digmann, DuBeau, Dombrowski, Flanagan, George, Harrington, Hines, Hollmann, Laird, and Steinman had no conflicts to disclose. Dr. Beizer is a consultant to LexiComp, Inc., a Wolters-Kluwer company. Dr. Fick is a consultant for Precision Health Economics. Dr. Holmes receives grant funding from Blue Cross/Blue Shield for a study on deprescribing. Dr. Linnebur is a Committee Member for both the Colorado Access Pharmacy and Therapeutics Committee and the CVS Pharmacy and Therapeutics Committee and has received honoraria from Springer Nature and Merck Manuals. Dr. Semla is a consultant to UnitedHealthcare and to LexiComp, Inc., a Wolters-Kluwer company; his spouse holds shares of Abbvie and Abbott stock.
Comment in
-
Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.J Am Geriatr Soc. 2023 Dec;71(12):3951-3953. doi: 10.1111/jgs.18579. Epub 2023 Sep 13. J Am Geriatr Soc. 2023. PMID: 37702478 No abstract available.
-
The importance of assessing the safe and effective use of oral anticoagulants in older adults.J Am Geriatr Soc. 2023 Dec;71(12):3954-3956. doi: 10.1111/jgs.18587. Epub 2023 Sep 22. J Am Geriatr Soc. 2023. PMID: 37738020 No abstract available.
-
Comment on the 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.J Am Geriatr Soc. 2024 Feb;72(2):631-633. doi: 10.1111/jgs.18721. Epub 2023 Dec 23. J Am Geriatr Soc. 2024. PMID: 38140884 No abstract available.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical